Analytical Data
-
Gene name
MAEA
- Application
-
Alternative Names
MAEA;EMP;E3 ubiquitin-Protein transferase MAEA
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7L5Y9
-
Expression Region
1-396aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMAVQESA AQLSMTLKVQ EYPTLKVPYE TLNKRFRAAQ KNIDRETSHV TMVVAELEKT LSGCPAVDSV VSLLDGVVEK LSVLKRKAVE SIQAEDESAK LCKRRIEHLK EHSSDQPAAA SVWKRKRMDR MMVEHLLRCG YYNTAVKLAR QSGIEDLVNI EMFLTAKEVE ESLERRETAT CLAWCHDNKS RLRKMKSCLE FSLRIQEFIE LIRQNKRLDA VRHARKHFSQ AEGSQLDEVR QAMGMLAFPP DTHISPYKDL LDPARWRMLI QQFRYDNYRL HQLGNNSVFT LTLQAGLSAI KTPQCYKEDG SSKSPDCPVC SRSLNKLAQP LPMAHCANSR LVCKISGDVM NENNPPMMLP NGYVYGYNSL LSIRQDDKVV CPRTKEVFHF SQAEKVYIM
-
Molecular Weight
48 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAEA (Myeloid-associated endothelial antigen) is a protein that has garnered significant attention in the field of immunology and cancer research due to its potential role in tumor biology and the immune response. Expressed primarily in endothelial cells, MAEA is implicated in the regulation of angiogenesis, the process through which new blood vessels form from existing ones, which is crucial for tumor growth and metastasis. Its association with myeloid cells suggests a potential involvement in the tumor microenvironment, influencing both the behavior of cancer cells and the function of immune cells. Research has shown that targeting MAEA may alter the tumor landscape, making it a promising candidate for therapeutic interventions. Recombinant MAEA proteins are being developed to facilitate studies on its function, interactions, and potential as a biomarker or therapeutic target. Understanding the molecular mechanisms underlying MAEA's role in cancer progression could provide insights into new treatment strategies and improve patient outcomes. As the scientific community continues to explore the intricacies of the tumor microenvironment, MAEA research holds the promise of unveiling novel pathways to manipulate for effective cancer therapies.
